No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
MBRX Moleculin Biotech
- 4.1000
- -0.2150-4.98%
Trading Jul 22 10:58 ET
9.48MMarket Cap-316P/E (TTM)
4.3900High4.1000Low988Volume4.3500Open4.3150Pre Close4.15KTurnover0.05%Turnover RatioLossP/E (Static)2.31MShares15.750052wk High0.44P/B8.52MFloat Cap3.215052wk Low--Dividend TTM2.08MShs Float731.7000Historical High--Div YieldTTM6.72%Amplitude3.2150Historical Low4.1960Avg Price1Lot Size
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Moleculin Biotech Advances AML Treatment After FDA Meeting
Moleculin Biotech Completes End Of Phase 2 Meeting With FDA For Annamycin In AML As Both First Line Therapy And For Subjects Who Are Refractory To Or Relapsed After Induction Therapy
Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses,
Express News | Moleculin Biotech Inc - Expects to Report Outcomes From Eop2 Meeting Upon Receipt of Official Minutes From FDA Which Is Expected by End of Q3 2024
Express News | Moleculin Completes End of Phase 2 Meeting With FDA for Annamycin in Aml
Moleculin Completes End of Phase 2 Meeting With FDA for Annamycin in AML
HOUSTON, July 10, 2024 — Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-
Roth MKM Maintains Moleculin Biotech(MBRX.US) With Buy Rating, Cuts Target Price to $40
Roth MKM analyst Jonathan Aschoff maintains $Moleculin Biotech(MBRX.US)$ with a buy rating, and adjusts the target price from $240 to $40.According to TipRanks data, the analyst has a success rate of
Comments
$Moleculin Biotech(MBRX.US$
Moleculin Completes End of Phase 2 Meeting with FDA for Annamycin in AML
Moleculin Biotech has completed its End of Phase 2 (EOP2) meeting with the FDA for its Phase 1B/2 clinical trial of Annamycin combined with Cytarabine for treating AML (MB-106). The meeting focused on reviewing clinical data and planning the next steps, with official outcomes expected by Q3 2024. Interim results show that out of 22 enrolled subjects, 45% achieved a composite complete remiss...
Moleculin Completes End of Phase 2 Meeting with FDA for Annamycin in AML
Moleculin Biotech has completed its End of Phase 2 (EOP2) meeting with the FDA for its Phase 1B/2 clinical trial of Annamycin combined with Cytarabine for treating AML (MB-106). The meeting focused on reviewing clinical data and planning the next steps, with official outcomes expected by Q3 2024. Interim results show that out of 22 enrolled subjects, 45% achieved a composite complete remiss...
$Moleculin Biotech(MBRX.US$ Moleculin Announces Additional Positive Preliminary Interim Data From Aml Clinical Trial! 89% Of Crc's Were Subjects With "Poor Prognosis" Cytogenetics and/or Mutations in Study! Annamycin Continues to Demonstrate No Cardiotoxicity! Current Median Durability of Response (Mdor) of Crc's = 6 Months and Increasing (N=9) in Study
$Moleculin Biotech(MBRX.US$ Means the stock will go on a run soon which will then be stopped by adding shares. If you buy you might wanf try to sell before it reaches 30% gains.
4
$Moleculin Biotech(MBRX.US$ Moleculin Announces Commencement of Nih-Funded Phase 2 Clinical Trial of Stat3 Inhibitor for the Treatment of Glioblastoma (Nu 21C06)
$Moleculin Biotech(MBRX.US$ Reuters· 1 min ago
Moleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for Annamycin
Moleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for Annamycin
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg